Biovica International
24.11.2021 08:22:00 CET | ACCESS Newswire | Press release
UPPSALA, SWEDEN / ACCESSWIRE / November 24, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica's blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer patients.
The study hypothesis is that incorporation of data from DiviTum®TKa measurements into the treatment monitoring of patients receiving standard first line treatment with CDK 4/6 inhibitors plus endocrine therapies, will be associated with the physicians' decision to change usage and/or timing of other routine monitoring tests such as CT scans and nuclear medicine exams. The study will examine care over time of 55 patients that will be tested regularly with DiviTum®TKa.
"We are proud to support the TK IMPACT study which is a key step forward in the development of DiviTum®TKa as it examines the clinical utility of the test on actual care of metastatic breast cancer patients. Our vision is to change the standard of care in monitoring to easy, fast and safe blood-based TKa testing", said Biovica's CEO Anders Rylander.
"An increasing number of our patients with metastatic breast cancer go for many months, even years, without their disease progressing. Nonetheless, as today's standard practice, we often bring them in for repeat imaging exams every three months. This is a burden on the patients. We believe that a convenient blood-based test will enable us to make changes that improve our patients' lives. We are excited to test our ability to make changes in this study" said Dr Nusayba Bagegni, the principal investigator of the study.
Earlier studies have demonstrated that patients with low TKa levels have extended times to disease progression, which enables the possibility to modify and reduce usage of other monitoring exams such as imaging. These other exams represent a burden both on patients and on healthcare costs.
To provide patients, their families, healthcare professionals, and the public with the information about the clinical trial, the TK IMPACT study is listed on the ClinicalTrials.gov website: ( https://clinicaltrials.gov/ct2/show/NCT04968964?term=Bagegni&draw=2&rank=1 )
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/674550/Biovica-Announces-the-Start-of-the-TK-IMPACT-Trial-at-Washington-University-of-St-Louis
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform15.5.2026 22:55:00 CEST | Press release
NESHER, ISRAEL / ACCESS Newswire / May 15, 2026 / Tabor Electronics today announced the commercial release of its Anti-Drone Test and Evaluation (T&E) solution, introducing a software-defined approach to validating counter-unmanned aircraft systems (C-UAS). Built on the company's Proteus™ Software Defined Radio (SDR) platform, the solution enables defense and security organizations to test and deploy counter-drone technologies in rapidly changing threat environments. As low-cost drones proliferate and communication protocols evolve, traditional hardware-bound test environments are struggling to keep pace. Tabor's platform replaces these constraints with a programmable framework that allows engineering teams to emulate and validate real-world RF scenarios in controlled lab environments-reducing reliance on extended field testing while accelerating development timelines. Originally developed in collaboration with leading anti-drone technology companies, the solution has already been prov
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program14.5.2026 21:05:00 CEST | Press release
Highlights: WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination Proposed transaction valued at approximately $15 million Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers TAMPA, FL / ACCESS Newswire / May 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million,
Karbon-X Explores Clean Cooking and Fish Smoking Climate Initiative Concept in Senegal14.5.2026 15:00:00 CEST | Press release
Concept contemplates future integration of digital monitoring technologies and community-focused climate infrastructure solutions. CALGARY, AB / ACCESS Newswire / May 14, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across compliance and voluntary carbon markets, today announced the exploration of a clean cooking and fish smoking climate initiative concept in Senegal focused on evaluating potential pathways for emissions reductions, improved fuel efficiency, and community-based climate infrastructure solutions. The initiative is currently at an early exploratory stage and is intended to assess opportunities associated with cleaner cooking technologies and, in later phases, more efficient fish smoking activities in rural communities. Traditional cooking and fish smoking practices continue to contribute to deforestation, indoor air pollution, and high fuel consumption across many regions. The concept contemp
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services13.5.2026 15:05:00 CEST | Press release
Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹ Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives Participating pharmacists expected to gain access to new clinical service revenue opportunities TAMPA, FL / ACCESS Newswire / May 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution compa
The White House Names Peter Arnell as U.S. Chief Brand Architect within the National Design Studio13.5.2026 13:00:00 CEST | Press release
The White House today announced Peter Arnell as the first-ever Chief Brand Architect of the United States, a founding role within the National Design Studio. WASHINGTON, D.C. / ACCESS Newswire / May 13, 2026 / The White House today announced Peter Arnell as the first-ever Chief Brand Architect of the United States, a founding role within the National Design Studio. Arnell will serve as Chief Brand Architect to Joe Gebbia, U.S. Chief Design Officer, working in direct partnership to accelerate the President's Executive Order 14338: "Improving Our Nation Through Better Design". Widely regarded as one of the world's foremost brand architects, Arnell brings 45 years of experience creating and transforming global brands, corporations, and institutions across technology, automotive, healthcare, consumer products, fashion, and sports, as well as major public and nonprofit organizations including the Special Olympics and the FDNY Foundation. As Chief Brand Architect for the nation, Arnell will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom